Vistagen (VTGN) - Cash on Hand per Share

Vistagen Therapeutics develops biologics for neurology, securing raw material supplies through long-term contracts. The trend of highly liquid assets per share confirms financial stability, with the indicator holding at 0.43. Vistagen Therapeutics is implementing innovative nasal sprays for anxiety, delegating the conduct of clinical trials to external contractors while strictly maintaining patent protection.
Comprehensive metric breakdowns and analytics for VistaGen Therapeutics, Inc. (VTGN)

For Vistagen Therapeutics (VTGN), operating in the high-risk biopharmaceutical sector, cash per share serves as a key indicator of survival. This metric reflects the amount of free capital available per share to fund operational activities. The calculation is based on the ratio of total liquid assets to the total number of shares outstanding. Amid constant losses and clinical trial expenses, this metric signals the proximity of the next secondary offering. A stable liquidity level confirms the company's ability to cover the risks associated with drug development failure.